Clinical Trial Update: Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 pediatric MATCH trial evaluating selpercatinib for patients with activating RET gene alterations across advanced solid tumors, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Hematopoietic and Lymphatic System Neoplasm
• Langerhans Cell Histiocytosis
• Medulloblastoma
• Neuroblastoma
• Osteosarcoma
• Soft Tissue Sarcoma
• Wilms Tumor

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-06